Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Vera Therapeutics (VERA – Research Report), retaining the price target of $70.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Rami Katkhuda has given his Buy rating due to a combination of factors surrounding Vera Therapeutics’ promising clinical developments and market potential. The company is on track to release significant Phase III ORIGIN 3 study results, which are anticipated to show a clinically meaningful benefit in proteinuria reduction. This outcome could pave the way for an accelerated approval of atacicept in treating IgAN, a condition with a growing market and room for multiple successful treatments.
Furthermore, despite the current market pressures and competitive landscape, Katkhuda sees a disconnect between Vera’s current valuation and the potential of atacicept. The drug has shown promising results in stabilizing kidney function in earlier studies, and there is optimism that it will perform well against competitors like Otsuka’s sibeprenlimab. These factors, combined with expert feedback on the evolving treatment landscape, underpin the Buy rating for Vera Therapeutics.
According to TipRanks, Katkhuda is a 4-star analyst with an average return of 13.4% and a 38.73% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., Tourmaline Bio, and VYNE Therapeutics.
In another report released on May 16, J.P. Morgan also maintained a Buy rating on the stock with a $68.00 price target.